Tüdőrák: vizsgálatok itt: Olaszország
272 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 15.. Ask the study team whether a trial fits you.
- 1. fázisTaking peoplePhase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Where
- Milan, Reggio Emilia
- Életkor
- 18 év to 100 év
- People
- 162 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06562192 - 2. fázisTaking peoplePhase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations
- Where
- Aviano, Bari, Genoa, Meldola, Monza, Naples, Novara, Parma, Pavia, Perugia, Rionero In Vulture, Rome, Varese
- Életkor
- 18 év and over
- People
- 35
- Run by
- Fondazione Ricerca Traslazionale
See details and how to join2025-520676-26-00 - 2. fázisBefejeződöttDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Ancona, Brescia, Candiolo, Milan, Parma, Rome
- Életkor
- 18 év and over
- People
- 204 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00 - 1. fázisTaking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Bologna, Milan, Verona
- Életkor
- 18 év and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - 1. fázisTaking peopleA Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Where
- Milan, Rozzano, Verona
- Életkor
- 18 év and over
- People
- 710 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT06179160 · EU 2023-507091-47-00 - 1. fázisNot yet taking people in OlaszországA Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
- Where
- Milan
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06476808 · EU 2025-523067-38-01 - 3. fázisBefejeződöttA Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
- Where
- Catania, Florence, Meldola, Modena, Naples, Padova, Pavia, Rome
- Életkor
- 18 év and over
- People
- 147 worldwide
- Run by
- Shanghai Junshi Biosciences Co. Ltd.
See details and how to join2023-507097-41-01 - No phaseTaking peopleIdentification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia
- Where
- Milan
- Életkor
- 18 év and over
- People
- 120
- Run by
- Fondazione Don Carlo Gnocchi ETS
See details and how to joinNCT07707245 - 1/2. fázisTaking peopleA Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- Where
- Milan, Ravenna, Rossano, Siena
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT07169734 · EU 2025-521441-24-00 - 2. fázisFut, nem toborozAutologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- Where
- Candiolo, Florence, Milan, Modena, Pavia, Pesaro
- Életkor
- 18 év to 70 év
- People
- 170 worldwide
- Run by
- Iovance Biotherapeutics, Inc.
See details and how to joinNCT04614103 · EU 2024-510778-26-00 - No phaseTaking peopleImpact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway
- Where
- Roma
- Életkor
- 18 év and over
- People
- 70
- Run by
- Regina Elena Cancer Institute
See details and how to joinNCT07649629 - 1. fázisTaking peopleTHE-0504 in Patients With Solid Tumors
- Where
- Rome
- Életkor
- 18 év and over
- People
- 30
- Run by
- Thena Biotech S.r.l.
See details and how to joinNCT07646106 · EU 2023-503787-17-00 - 2/3. fázisNot yet taking people in OlaszországA Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36
- Where
- Aviano, Candiolo, Catania, Guastalla, Meldola, Milan, Monza, Naples, Padova, Piacenza, Reggio Emilia, Rome, Rozzano MI, Trento
- Életkor
- 18 év and over
- People
- 36
- Run by
- IRCCS Istituto Nazionale Tumori Fondazione Pascale
See details and how to join2025-522084-15-00 - No phaseTaking peopleImmune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer Patients
- Where
- Rome
- Életkor
- 18 év and over
- People
- 150
- Run by
- Regina Elena Cancer Institute
See details and how to joinNCT07637474 - 2. fázisTaking peopleAssociation of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
- Where
- Rome
- Életkor
- 18 év and over
- People
- 37
- Run by
- Regina Elena Cancer Institute
See details and how to joinNCT06771518 - No phaseTaking peopleStandardization of a Platform of Preclinical Models Derived From NSCLC Patients
- Where
- Rome
- Életkor
- 18 év and over
- People
- 5
- Run by
- Regina Elena Cancer Institute
See details and how to joinNCT07629375 - 2. fázisNot yet taking people in OlaszországPhase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
- Where
- Brescia, Milan, Rome, Udine
- Életkor
- 18 év and over
- People
- 158 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT07234877 · EU 2025-522985-60-00 - 2. fázisNot yet taking people in OlaszországPhase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with anaplastic lymphoma kinase positive (ALK+) locally advanced Stage III Non Small Cell Lung Cancer (NSCLC): ALNEO trial-GOIRC-01-2020
- Where
- Aviano, Bari, Bologna, Camaiore, Catania, Florence, Meldola, Modena, Monza, Naples, Orbassano, Padova, Parma, Perugia, Rome, Rozzano, Verona
- Életkor
- 18 év and over
- People
- 33
- Run by
- G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
See details and how to join2024-519106-12-00 - 2. fázisTaking peopleNiraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
- Where
- Meldola, Milan, Perugia, Treviso
- Életkor
- 18 év and over
- People
- 44 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT05718323 · EU 2022-502092-33-00 - 1/2. fázisFut, nem toborozA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Where
- Aviano, Milan, Rome
- Életkor
- 12 év and over
- People
- 500 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00 - 2. fázisNot yet taking people in OlaszországA Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with pleural mesothelioma positive for PD-L1 expression and germline or somatic mutations in the HRR genes
- Where
- Acquaviva delle Fonti, Aviano, Bari, Catania, Florence, Genoa, Lecce, Meldola, Messina, Monza, Naples, Orbassano, Padova, Pavia, Pesaro, Reggio Emilia, Varese, IRCCS Istituti Fisioterapici Ospitalieri- Istituto Nazionale tumori Regina Elena
- Életkor
- 18 év and over
- People
- 48
- Run by
- Universita' Degli Studi Di Torino
See details and how to joinNCT04940637 · EU 2024-515555-38-01 - 3. fázisNot yet taking people in OlaszországPhase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- Where
- Milan, Naples, Olbia, Orbassano, Rome, Rozzano
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Nuvation Bio Inc.
See details and how to joinNCT07154706 · EU 2025-521971-29-00 - 1. fázisTaking peoplePhase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
- Where
- Milan, Reggio Emilia
- Életkor
- 18 év and over
- People
- 76 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2023-510356-23-00 - 3. fázisTaking peopleEfficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
- Where
- Bari, Meldola, Milan, Reggio Emilia, Roma, Verona
- Életkor
- 18 év and over
- People
- 170 worldwide
- Run by
- Grupo Espanol de Tumores Neuroendocrinos
See details and how to joinNCT05918302 · EU 2022-502154-13-00 - 2. fázisNot yet taking people in OlaszországPhase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
- Where
- Milan, Padova, Rome
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- Advenchen Pharmaceuticals, LLC.
See details and how to joinNCT05363280 · EU 2023-509067-24-01